Celgene Corporation (Nasdaq: CELG until 2019) was a biopharmaceutical company headquartered at 86 Morris Avenue, Summit, New Jersey. It was spun off from Celanese in 1986 (some sources cite a 1980 origin) and was acquired by Bristol-Myers Squibb in November 2019 for roughly $74 billion — the largest pharmaceutical acquisition at the time. Celgene now operates as a BMS subsidiary/brand rather than an independent public company; its shares no longer trade. Pre-acquisition, its 2018 revenue was approximately $15.3 billion, with roughly 8,000-plus employees globally.
Products / operations. Celgene discovered, developed, and commercialized therapies for cancer and inflammatory disease. Its principal marketed products were Revlimid (lenalidomide) for multiple myeloma and myelodysplastic syndromes; Pomalyst/Imnovid (pomalidomide) for multiple myeloma; Abraxane (nab-paclitaxel) for several solid tumors; Thalomid (thalidomide); and Otezla (apremilast) for psoriasis/psoriatic arthritis — Otezla was divested to Amgen in 2019 as an antitrust condition of the BMS deal. These brands now sit within BMS's legacy portfolio.
Patent-litigation posture. Celgene is an operating company, not a non-practicing entity, and litigates in both directions. Its 21 plaintiff-side cases are almost entirely Hatch-Waxman/ANDA patent suits against generic filers — Cipla, Dr. Reddy's, Hetero Labs, MSN Laboratories, Apotex, and Hikma — concentrated in the District of New Jersey, its home venue. Its 19 defendant-side cases are predominantly antitrust and pay-for-delay/price-fixing claims brought by health insurers, PBMs, and payers seeking damages related to Revlimid and Thalomid.
Notable cases. In re Revlimid & Thalomid Purchaser Antitrust Litigation (D.N.J., 2019) anchors the defendant-side cluster, alongside suits by Cigna, CenterWell, UnitedHealthcare, Molina Healthcare, Blue Cross Blue Shield, and MSP Recovery Claims. On the plaintiff side, Celgene Corp. v. Cipla and Celgene Corp. v. Dr. Reddy's Laboratories reflect the recurring lenalidomide patent disputes and their Federal Circuit appeals. No cases appear in plaintiff-friendly Eastern District of Texas; the docket is New Jersey- and New York-centric.